Shares of Novavax Inc (NASDAQ:NVAX) are up 8.12% to $4.26 in pre-market trade after the clinical stage biopharmaceutical company said its respiratory ailment vaccine candidate for women of childbearing age in a Phase 2 study showed positive results, the Wall Street Journal reports.Novavax, Inc. (NASDAQ:NVAX) shares after opening at $4.25 moved to $4.63 on last trade day and at the end of the day closed at $4.49 . Company price to sales ratio in past twelve months was calculated as 44.91 and price to cash ratio as 7.05. Novavax, Inc. (NASDAQ:NVAX) showed a positive weekly performance of 4.18%.
Amicus Therapeutics , Inc. (NASDAQ:FOLD) a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced positive 12- and 24-month data from its first Phase 3 study (Study 011) of the oral small molecule chaperone migalastat HCl (“migalastat”) monotherapy in Fabry patients with amenable mutations. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares advanced 20.65% in last trading session and ended the day on $2.22. FOLD return on equity ratio is recorded as -144.30% and its return on assets is -100.50%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) yearly performance is -31.06%.
XOMA Corporation (NASDAQ:XOMA) a leader in the discovery and development of therapeutic antibodies, announced that based on its meeting with the U.S Food and Drug Administration (FDA), the Company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. During the meeting, the Company and the FDA reviewed the data generated from XOMA’s pilot trial in six PG patients. XOMA Corp (NASDAQ:XOMA) shares moved up 20.16% in last trading session and was closed at $4.59 while trading in range of $4.02 – $4.85 – XOMA Corp (NASDAQ:XOMA) year to date (YTD) performance is -31.80%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). The data demonstrate robust antibody and T cell responses and evidence of clinical benefit in patients with very advanced cancers and suggest that CDX-1401 may predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. CDX-1401 is an off-the-shelf vaccine consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is -7.68%. On last trading day company shares ended up $14.78. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -31.01%. Analysts mean target price for the company is $36.33.
Leave a Reply